Raymond James & Associates’s Cardlytics CDLX Stock Holding History

Raymond James & Associates’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-244	Closed	-$310K	–	4133
2021 Q2	$310K	Buy	+244	New	+$275K	﹤0.01%	3415
2021 Q1	–	Sell	-143	Closed	-$203K	–	4009
2020 Q4	$203K	Sell	143 -1,189	-89%	-$1.27M	﹤0.01%	3392
2020 Q3	$940K	Buy	1,332 +790	+146%	+$574K	﹤0.01%	2211
2020 Q2	$380K	Sell	542 -154	-22%	-$88.9K	﹤0.01%	2783
2020 Q1	$243K	Sell	696 -361	-34%	-$256K	﹤0.01%	2909
2019 Q4	$665K	Buy	+1,057	New	+$517K	﹤0.01%	2527
2019 Q2	–	Sell	-6,419	Closed	-$1.06M	–	3656
2019 Q1	$1.06M	Buy	6,419 +1,039	+19%	+$169K	﹤0.01%	2164
2018 Q4	$583K	Buy	5,380 +3,970	+282%	+$669K	﹤0.01%	2449
2018 Q3	$353K	Buy	+1,410	New	+$303K	﹤0.01%	2937

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Raymond James & Associates's CDLX Position: Q3 2021 in Review

Raymond James & Associates sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 244 shares — an estimated $310K sold.

Raymond James & Associates first reported a position in CDLX in Q3 2018 and held it in 9 quarters. The position peaked at $1.06M in Q1 2019. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

Raymond James & Associates reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
Raymond James & Associates sold 244 Cardlytics shares in Q3 2021, an estimated $310K.
Raymond James & Associates first reported a position in Cardlytics in Q3 2018 and held it in 9 quarters.
Raymond James & Associates's Cardlytics position peaked at $1.06M in Q1 2019.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.